Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

SELLAS Life Sciences (SLS) Change in Receivables (2022)

SELLAS Life Sciences (SLS) has disclosed Change in Receivables for 1 consecutive years, with $1.0 million as the latest value for Q1 2022.

Quarterly Change in Receivables changed N/A to $1.0 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Mar 2023, changed 0.0% year-over-year, with the annual reading at -$1.6 million for FY2014, 144.64% down from the prior year.
Change in Receivables for Q1 2022 was $1.0 million at SELLAS Life Sciences.
The five-year high for Change in Receivables was $1.0 million in Q1 2022, with the low at $1.0 million in Q1 2022.